Skip to Content
U.S. National Institutes of Health
Cancer Diagnosis Program Cancer Imaging Program Cancer Therapy Evaluation Program Developmental Therapeutics Program Radiation Research Program Translational Research Program Biometric Research Branch Office of Cancer Complementary and Alternative Medicine
Last Updated: 04/11/2014

Spotlight On…

An Open Letter to the Cancer Community Regarding Community Clinical Trials
As you are aware, the National Cancer Institute (NCI) is in the process of combining its two community-based research networks to create a single network that builds on the strengths of the Community Clinical Oncology Program/Minority-Based Community Clinical Oncology Program (CCOPs) and the NCI Community Cancer Centers Program (NCCCP). More…

DCTD 2010 Program Accomplishments
This edition of Program Accomplishments of the Division of Cancer Treatment and Diagnosis offers a multi-year review of the undertakings and achievements of this segment of the National Cancer Institute. More…

Changing the Face of NCI-Supported Early Phase Therapeutic Trials
These presentations to the Clinical Trial and Translational Research Advisory Committee on March 7, 2012, outline a plan to redesign the NCI Early Therapeutics Program. More…

U10 Cooperative Agreement for NCI Clinical Trials Network: Request for Application Concerning Cooperative Groups Reorganization
This presentation to the National Cancer Advisory Board on February 28, 2012, delineates the background and plans for the funding opportunity currently under development to improve late phase cancer clinical trials. More…

Transforming the NCI’s Clinical Trials System
On March 1, 2012, Dr. James H. Doroshow presented to the NCI Board of Scientific Advisors a summary of the plans and progress to transform the NCI Clinical Trials Program. More…

Approved Cancer Treatment Drugs Developed with DTP Involvement
The DCTD Developmental Therapeutics Program was instrumental in the discovery or development of 45 drugs currently available for treating cancer. More…

Selected Major Accomplishments of CTEP
From 2005 to 2011, the DCTD Cancer Therapy Evaluation Program developed practice-changing clinical trials, new FDA indications, and new indications of generic agents. More…

Transforming the NCI Clinical Trials Enterprise Website
For over 50 years, NCI has supported a standing--the NCI Clinical Trials Cooperative Group Program — to conduct large scale cancer clinical trials across the nation, with successful completion of many important trials that have led to new treatments for cancer patients. More…

Approved Oncology Drugs Now Available from DCTD in Plated Sets
More than 50 oncology drugs approved by the Food and Drug Administration are now available from DCTD in plated sets for drug discovery efforts. Researchers may use the sets for many potential purposes, including comparing their compounds with approved oncology drugs and performing drug combination studies. More…

Clinical and Translational Advisory Committee (CTAC)
An external NCI committee that shall provide advice to NCI on the NCI-supported national clinical trials and translational research enterprises… More…

Clinical and Translational Research Operations Committee (CTROC)
This committee is designed to coordinate clinical trials and translational programs across the institute and to make recommendations to improve cost-effectiveness and reduce duplication and overlap among NCI components. CTROC will also evaluate new Requests for Applications and Program Announcements in these research areas prior to review by the NCI Executive Committee. More…

NCI’s Clinical Trials Cooperative Groups National Meeting Report
This report highlights recent important research findings presented by the NCI-sponsored Clinical Trials Cooperative Group Program at major national conferences. Reports are published online twice yearly. More…

Archive

Clinical Trials Working Group (CTWG)
The Clinical Trials Working Group (CTWG), which made 22 recommendations to the National Cancer Advisory Board in 2005 to revamp the NCI's cancer clinical trials system, spawned a new NCI organizational structure designed to oversee the institute's entire clinical trials enterprise. More…

ABT-888 (NSC 737664)
ABT-888, an orally bioavailable PARP-inhibitor developed by Abbott Laboratories, significantly enhanced the antitumor activity of DNA-damaging agents and radiation in preclinical models. More…

Aminoflavone Prodrug (NSC 710464)
The parent aminoflavone (NSC 686288) showed good differential activity in the NCI 60-cell line screen and marked effects in renal xenografts. More…

Batracylin (NSC 320846)
Batracylin reached Stage 3 of the NCI pipeline, but was dropped in 1989 because of concern about the interspecies differences in toxicity and potential for variable oral absorption. More…

Camptothecins (NSC 94600, 609699, 616348)
Camptothcin (NSC 94600) was first isolated by Wall from a sample of Camptotheca acuminata. More…

Carboplatin (NSC 241240)
The utility of platinum compounds in the treatment of cancer was recognized in the 1970s with the development of cisplatin, which was approved by the FDA for use in testicular and ovarian cancer in 1978. More…

Halichondrin B analog (NSC 707389)
Work done on synthesizing halicondrin B (NSC 609395) showed that only a portion of the molecule was needed for potent biological activity.More…

SAHA (NSC 701852)
SAHA is a potent histone deactylase (HDAC) inhibitor with excellent oral bioavailability. More…

Tandutinib (MLN518)
MLN518 is a potent, ATP-competitive and reversible inhibitor of Type III receptor tyrosine kinases (RTKs). More…